Difference between revisions of "Part:BBa K774000:Experience"
(→Applications of BBa_K774000) |
|||
| Line 1: | Line 1: | ||
| − | |||
__NOTOC__ | __NOTOC__ | ||
This experience page is provided so that any user may enter their experience using this part.<BR>Please enter | This experience page is provided so that any user may enter their experience using this part.<BR>Please enter | ||
| Line 5: | Line 4: | ||
===Applications of BBa_K774000=== | ===Applications of BBa_K774000=== | ||
| + | |||
| + | A hybrid of the PyeaR promoter (BBaK216005) and the E9-ns2 CArG promoter (Ref:1). Two versions will be synthesised, with the promoters altering their position in relation to the 5’-end of the sequence. | ||
| + | |||
| + | To provide additional restriction enzyme sites that may become useful during later cloning steps, BamHI, HindIII and NdeI have been added between the 2 promoters. | ||
| + | |||
| + | It is envisaged that any open reading frame (e.g. RFP or GFP) will be cloned “downstream” (i.e. at the 3’-end) of these promoter sequences. | ||
| + | |||
| + | |||
| + | Ref:1 | ||
| + | |||
| + | Scott, S.D., Joiner, M.C. & Marples, B., 2002. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene therapy, 9(20), p.1396-402. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12365005 [Accessed June 24, 2012]. | ||
===User Reviews=== | ===User Reviews=== | ||
Revision as of 16:40, 25 June 2012
This experience page is provided so that any user may enter their experience using this part.
Please enter
how you used this part and how it worked out.
Applications of BBa_K774000
A hybrid of the PyeaR promoter (BBaK216005) and the E9-ns2 CArG promoter (Ref:1). Two versions will be synthesised, with the promoters altering their position in relation to the 5’-end of the sequence.
To provide additional restriction enzyme sites that may become useful during later cloning steps, BamHI, HindIII and NdeI have been added between the 2 promoters.
It is envisaged that any open reading frame (e.g. RFP or GFP) will be cloned “downstream” (i.e. at the 3’-end) of these promoter sequences.
Ref:1
Scott, S.D., Joiner, M.C. & Marples, B., 2002. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene therapy, 9(20), p.1396-402. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12365005 [Accessed June 24, 2012].
User Reviews
UNIQc5abdc1e9d88eaa4-partinfo-00000000-QINU UNIQc5abdc1e9d88eaa4-partinfo-00000001-QINU